山东大学耳鼻喉眼学报 ›› 2022, Vol. 36 ›› Issue (2): 7-14.doi: 10.6040/j.issn.1673-3770.0.2021.318

• • 上一篇    下一篇

中耳间变性大T细胞淋巴瘤1例并文献复习

赵笑冰,张大为,陈仁杰   

  1. 南京医科大学第二附属医院 耳鼻咽喉头颈外科, 江苏 南京 210000
  • 发布日期:2022-04-15
  • 通讯作者: 陈仁杰. E-mail:renjiechenent@aliyun.com
  • 基金资助:
    江苏省青年医学人才项目(QNRC2016679)

A case of middle-ear anaplastic large T- cell lymphoma and literature review

ZHAO Xiaobing,ZHANG Dawei, CHEN Renjie   

  1. Department of Otorhinolaryngology & Head and Neck Surgery, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210000, Jiangsu, China
  • Published:2022-04-15

PDF (PC)

92

摘要： 目的 探讨中耳间变性大T细胞淋巴瘤的临床特点及诊疗方法,以便对其进行早期诊断。 方法 回顾性分析1例中耳间变性大T细胞淋巴瘤患者的临床资料并复习相关文献进行总结。 结果 淋巴瘤多发生于骨骼、骨髓、皮下组织和脾脏,发生于中耳者罕见。中耳淋巴瘤起病时均无浅表淋巴结肿大,通常表现为耳痛、听力下降及耳内溢液(浆液性、脓性或血性),病情进展,可出现周围性面瘫及颅内外并发症。CT影像学表现可见软组织密度较高且不均匀,骨质破坏不规则、呈虫蚀样,病变范围广,增强扫描可见强化明显。确诊需病理活检及免疫组化,以化学治疗为主。 结论 中耳间变性大T细胞淋巴瘤极为罕见,且临床及影像学表现无特异性,因而详细的病史采集、全身系统检查、病理活检及免疫组化等手段对于早期诊断疾病非常重要。

关键词: 中耳, 肿瘤, 间变性大T细胞淋巴瘤, 免疫组合化学, 耳外科手术

Abstract: Objective To investigate the clinical characteristics, diagnosis and treatment methods of middle ear anaplastic large T-cell lymphoma, to enable its early diagnosis. Methods A patient with middle ear anaplastic large T-cell lymphoma was retrospectively reviewed,along with previous cases of middle ear lymphoma found in the literature. Results Lymphoma mostly occurs in the bones, bone marrow, subcutaneous tissue and spleen, but rarely in the middle ear. There is no superficial lymphadenopathy at the onset of middle ear lymphoma, which usually presents as earache, hearing loss, and ear discharge(serous, purulent, or bloody). Disease progression, peripheral facial nerve paralysis and extra cranial-intracranial complications may occur. The lesion appeared as a high and uneven soft tissue density on the CT and the bone destruction was irregular and worm-eaten. The lesion area was wide and the enhanced scan showed obvious enhancement. Diagnosis requires pathological biopsy and immunohistochemistry. Chemotherapy is the main treatment. Conclusion Middle ear anaplastic large T-cell lymphoma is extremely rare and its clinical and imaging findings are non-specific. Therefore it is imperative to carefully consider the patient’s medical history, systemic examination findings, pathological biopsy findings and immunohistochemistry to diagnose middle ear anaplastic large T-cell lymphoma at an early stage.

Key words: Middle ear, Tumor, Anaplastic large T cell lymphoma, Immunocombination chemistry, Otology surgery

中图分类号: 

  • R764.92
[1] 文锋, 王冰洁, 扈希昊, 等. 咽淋巴环套细胞淋巴瘤4例及文献复习[J]. 山东大学耳鼻喉眼学报, 2020,34(1): 115-120. doi: 10.6040/j.issn.1673-3770.0.2019.490. WEN Feng, WANG Bingjie, HU Xihao, et al. Mantle cell lymphoma involving the Waldeyer's ring: a case series and literature review[J]. J Otolaryngol Ophthalmol Shandong Univ, 2020, 34(1): 115-120. doi: 10.6040/j.issn.1673-3770.0.2019.490.
[2] 杨国溜, 陈良远, 欧巧萍. 外周血EB病毒DNA与非霍奇金淋巴瘤的预后相关性研究[J]. 国际检验医学杂志, 2020,41(3): 290-292,296. doi: CNKI:SUN:GWSQ.0.2020-03-009. YANG Guoliu, CHEN Liangyuan, OU Qiaoping. Study on the relationship between Epstein-Barr virus DNA and prognosis of non-Hodgkin's lymphoma[J]. Int J Lab Med, 2020,41(3): 290-292,296. doi: CNKI:SUN:GWSQ.0.2020-03-009.
[3] Chihara D, Fanale MA. Management of anaplastic large cell lymphoma[J]. Hematol Oncol Clin North Am, 2017, 31(2): 209-222. doi:10.1016/j.hoc.2016.11.001.
[4] Al-Hamadani M, Habermann TM, Cerhan JR, et al. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011[J]. Am J Hematol, 2015, 90(9): 790-795. doi:10.1002/ajh.24086.
[5] Adams SV, Newcomb PA, Shustov AR. Racial patterns of peripheral T-cell lymphoma incidence and survival in the United States[J]. J Clin Oncol, 2016, 34(9): 963-971. doi:10.1200/JCO.2015.63.5540.
[6] Box JK, Paquet N, Adams MN, et al. Nucleophosmin: from structure and function to disease development[J]. BMC Mol Biol, 2016, 17(1): 19. doi:10.1186/s12867-016-0073-9.
[7] Montes-Mojarro IA, Steinhilber J, Bonzheim I, et al. The pathological spectrum of systemic anaplastic large cell lymphoma(ALCL)[J]. Cancers(Basel), 2018, 10(4): E107. doi:10.3390/cancers10040107.
[8] Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20): 2375-2390. doi:10.1182/blood-2016-01-643569.
[9] Mora J, Filippa DA, Thaler HT, et al. Large cell non-Hodgkin lymphoma of childhood: Analysis of 78 consecutive patients enrolled in 2 consecutive protocols at the Memorial Sloan-Kettering Cancer Center[J]. Cancer, 2000, 88(1): 186-197. doi:10.1002/(sici)1097-0142(20000101)88: 1<186: aid-cncr26>3.0.co;2-5.
[10] Stein H, Foss HD, Dürkop H, et al. CD30(+)anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features[J]. Blood, 2000, 96(12): 3681-3695. doi: 10.1053/beha.2000.0100.
[11] King RL, Dao LD, McPhail ED, et al. Morphologic features of ALK-negative anaplastic large cell lymphomas with DUSP22 rearrangements[J]. Am J Surg Pathol, 2016, 40(1): 36-43. doi:10.1097/PAS.0000000000000500.
[12] Shustov A, Soma L. Anaplastic large cell lymphoma: contemporary concepts and optimal management[J]. Cancer Treat Res, 2019, 176: 127-144. doi:10.1007/978-3-319-99716-2_6.
[13] Agnelli L, Mereu E, Pellegrino E, et al. Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma[J]. Blood, 2012, 120(6): 1274-1281. doi:10.1182/blood-2012-01-405555.
[14] Pedersen MB, Hamilton-Dutoit SJ, Bendix K, et al. Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma Registry[J]. Hematol Oncol, 2015, 33(4): 120-128. doi:10.1002/hon.2153.
[15] 陈英坤, 俞文娟, 刘辉, 等. 原发系统型间变性大细胞淋巴瘤40例临床特征及预后分析[J]. 中华血液学杂志, 2020(3): 222-227. doi: 10.3760/cma.j.issn.0253-2727.2020.03.007. Chen Yingkun, Yu Wenjuan, Liu Hui, et al. Clinical features and prognosis analysis of 40 cases of primary systemic anaplastic large cell lymphoma[J]. Chinese Journal of Hematology, 2020(3): 222-227. doi: 10.3760/cma.j.issn.0253-2727.2020.03.007.
[16] Allen CE, Kelly KM, Bollard CM. Pediatric lymphomas and histiocytic disorders of childhood[J]. Pediatr Clin North Am, 2015, 62(1): 139-165. doi:10.1016/j.pcl.2014.09.010.
[17] Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project[J]. Blood, 2008, 111(12): 5496-5504. doi:10.1182/blood-2008-01-134270.
[18] Ceccon M, Merlo MEB, Mologni L, et al. Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency[J]. Oncogene, 2016, 35(29): 3854-3865. doi:10.1038/onc.2015.456.
[19] Zeng Y, Feldman AL. Genetics of anaplastic large cell lymphoma[J]. Leuk Lymphoma, 2016, 57(1): 21-27. doi:10.3109/10428194.2015.1064530.
[20] Hapgood G, Savage KJ. The biology and management of systemic anaplastic large cell lymphoma[J]. Blood, 2015, 126(1): 17-25. doi:10.1182/blood-2014-10-567461.
[21] 何健, 钱立庭, 高劲. 外耳道腺样囊性癌侵犯中耳、颞叶且伴颈部淋巴结转移一例报告[J]. 山东大学耳鼻喉眼学报, 2018,32(6): 109-111,118. doi: 10.6040/j.issn.1673-3770.0.2017.424. HE Jian, QIAN Liting, GAO Jin. A case of external auditory canal adenoid cystic carcinoma invading the middle ear and temporal lobe, with cervical lymph node metastasis[J]. J Otolaryngol Ophthalmol Shandong Univ, 2018,32(6): 109-111,118. doi: 10.6040/j.issn.1673-3770.0.2017.424.
[22] Thakral B, Zhou J, Medeiros LJ. Extranodal hematopoietic neoplasms and mimics in the head and neck: an update[J]. Hum Pathol, 2015, 46(8): 1079-1100. doi:10.1016/j.humpath.2015.05.007.
[23] Alqunaee M, Aldaihani A, AlHajery M. Non-Hodgkin's lymphoma of the middle ear presenting as mastoiditis[J]. Case Rep Otolaryngol, 2018, 2018: 7639784. doi:10.1155/2018/7639784.
[24] 孟琳, 姜妍, 余晔. 中耳恶性淋巴瘤一例[J]. 听力学及言语疾病杂志, 2020,28(6): 725-727. doi: 10.3969/j.issn.1006-7299.2020.06.027.
[25] Tram Do B, Charpentier AM, Bourré-Tessier J, et al. Unusual presentation for small lymphocytic lymphoma: Case report of a man with bilateral ear involvement and review of the literature[J]. Eur Ann Otorhinolaryngol Head Neck Dis, 2019, 136(3S): S45-S47. doi:10.1016/j.anorl.2018.10.017.
[26] Danino J, Joachims HZ, Ben-Arieh Y, et al. T cell lymphoma of the ear presenting as mastoiditis[J]. J Laryngol Otol, 1997, 111(9): 852-854. doi:10.1017/s0022215100138794.
[27] Li B, Liu SX, Yang H, et al. Primary T-cell lymphoblastic lymphoma in the middle ear[J]. Int J Pediatr Otorhinolaryngol, 2016, 82: 19-22. doi:10.1016/j.ijporl.2015.12.020.
[28] Jain P, Fayad LE, Rosenwald A, et al. Recent advances in de novo CD5+diffuse large B cell lymphoma[J]. Am J Hematol, 2013, 88(9): 798-802. doi:10.1002/ajh.23467.
[29] Hart S, Horsman JM, Radstone CR, et al. Localised extranodal lymphoma of the head and neck: the Sheffield Lymphoma Group experience(1971-2000)[J]. Clin Oncol(R Coll Radiol), 2004, 16(3): 186-192. doi:10.1016/j.clon.2003.10.010.
[30] Jackson R, Addison AB, Prinsley PR. Cholesteatoma in children and adults: are there really any differences?[J]. J Laryngol Otol, 2018, 132(7): 575-578. doi:10.1017/S0022215118000890.
[31] Yung M, Tono T, Olszewska E, et al. EAONO/JOS joint consensus statements on the definitions, classification and staging of middle ear cholesteatoma[J]. J Int Adv Otol, 2017, 13(1): 1-8. doi:10.5152/iao.2017.3363.
[32] 杨扬, 肖潇, 陈敏, 等. 儿童中耳胆脂瘤JOS分期及其临床特征[J]. 山东大学耳鼻喉眼学报, 2019,33(05), 33: 52-55. doi: 10.6040/j.issn.1673-3770.0.2019.376. YANG Yang, XIAO Xiao, CHEN Min, et al. JOS staging and clinical features of middle ear cholesteatoma in children[J]. J Otolaryngol Ophthalmol Shandong Univ, 2019,33(05), 33: 52-55. doi: 10.6040/j.issn.1673-3770.0.2019.376.
[33] Gomaa MA, Abdel Karim AR, Abdel Ghany HS, et al. Evaluation of temporal bone cholesteatoma and the correlation between high resolution computed tomography and surgical finding[J]. Clin Med Insights Ear Nose Throat, 2013, 6: 21-28. doi:10.4137/CMENT.S10681.
[34] Wallis S, Atkinson H, Coatesworth A P. Chronic otitis media[J]. Postgrad Med, 2015, 127(4): 391-395. doi: 10.1080/00325481.2015.1027133.
[35] Jaisinghani VJ, Paparella MM, Schachern PA, et al. Tympanic membrane/middle ear pathologic correlates in chronic otitis media[J]. Laryngoscope, 1999, 109(5): 712-716. doi:10.1097/00005537-199905000-00007.
[36] 杨昌秀. 46例中耳胆脂瘤的临床特征及手术疗效分析[J]. 现代临床医学, 2020, 46(6): 425-428. doi:10.11851/j.issn.1673-1557.2020.06.009. YANG Changxiu. Clinicalfeature and operative effect of 46 cases of middle ear of cholesteatoma[J]. J Mod Clin Med, 2020, 46(6): 425-428. doi:10.11851/j.issn.1673-1557.2020.06.009.
[37] Ayache D, Darrouzet V, Dubrulle F, et al. Imaging of non-operated cholesteatoma: clinical practice guidelines[J]. Eur Ann Otorhinolaryngol Head Neck Dis, 2012, 129(3): 148-152. doi:10.1016/j.anorl.2011.09.005.
[38] Mileshina NA, Kurbatova EV. Cholesteatoma of the external and middle ear in the childhood[J]. Vestn Otorinolaringol, 2015(1): 25-27. doi:10.17116/otorino201580125-27.
[39] Yates PD, Flood LM, Banerjee A, et al. CT scanning of middle ear cholesteatoma: what does the surgeon want to know?[J]. Br J Radiol, 2002, 75(898): 847-852. doi:10.1259/bjr.75.898.750847.
[40] Mittal R, Lisi CV, Gerring R, et al. Current concepts in the pathogenesis and treatment of chronic suppurative otitis media[J]. J Med Microbiol, 2015, 64(10): 1103-1116. doi:10.1099/jmm.0.000155.
[41] Filipe M, Reimer Å, Matuschek E, et al. Fluoroquinolone-resistant Alcaligenes faecalis related to chronic suppurative otitis media, Angola[J]. Emerg Infect Dis, 2017, 23(10): 1740-1742. doi:10.3201/eid2310.170268.
[42] Varshney S, Nangia A, Bist SS, et al. Ossicular chain status in chronic suppurative otitis media in adults[J]. Indian J Otolaryngol Head Neck Surg, 2010, 62(4): 421-426. doi:10.1007/s12070-010-0116-3.
[43] Majeed J, Sudarshan Reddy L. Role of CT mastoids in the diagnosis and surgical management of chronic inflammatory ear diseases[J]. Indian J Otolaryngol Head Neck Surg, 2017, 69(1): 113-120. doi:10.1007/s12070-016-1023-z.
[44] Brennan-Jones CG, Head K, Chong LY, et al. Topical antibiotics for chronic suppurative otitis media[J]. Cochrane Database Syst Rev, 2020, 1: CD013051. doi:10.1002/14651858.CD013051.pub2.
[45] Gendeh HS, Abdullah AB, Goh BS, et al. Intracranial complications of chronic otitis media: why does it still occur?[J]. Ear Nose Throat J, 2019, 98(7): 416-419. doi:10.1177/0145561319840166.
[46] Ellin F, Landström J, Jerkeman M, et al. Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study[J]. Blood, 2015, 126(1): 36-41. doi:10.1182/blood-2014-12-616961.
[47] 刘丁丁, 钱晓云, 刘永泽, 等. 84例原发头颈部淋巴瘤临床及病理特征分析[J]. 山东大学耳鼻喉眼学报, 2018,32(6): 48-51. doi: 10.6040/j.issn.1673-3770.0.2018.274. LIU Dingding, QIAN Xiaoyun, LIU Yongze, et al. Analysis of clinical and pathological features of 84 patients with primary head and neck lymphoma[J]. J Otolaryngol Ophthalmol Shandong Univ, 2018,32(6): 48-51. doi: 10.6040/j.issn.1673-3770.0.2018.274.
[48] Cederleuf H, Bjerregård Pedersen M, Jerkeman M, et al. The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: a Nordic Lymphoma Group study[J]. Br J Haematol, 2017, 178(5): 739-746. doi:10.1111/bjh.14740.
[49] Ganesan P, Joshua T, Sundersingh S, et al. Refractory ALK-positive anaplastic large cell lymphoma: long term survival with crizotinib[J]. Indian J Hematol Blood Transfus, 2018, 34(2): 353-354. doi:10.1007/s12288-017-0889-6.
[50] Vu K, Ai WY. Update on the treatment of anaplastic large cell lymphoma[J]. Curr Hematol Malig Rep, 2018, 13(2): 135-141. doi:10.1007/s11899-018-0436-z.
[51] Piccaluga PP, Fuligni F, de Leo A, et al. Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study[J]. J Clin Oncol, 2013, 31(24): 3019-3025. doi:10.1200/JCO.2012.42.5611.
[52] Wilhelm M, Smetak M, Reimer P, et al. First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation[J]. Blood Cancer J, 2016, 6(7): e452. doi:10.1038/bcj.2016.63.
[53] Dhawale TM, Shustov AR. Autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas: a histology-specific review[J]. Hematol Oncol Clin North Am, 2017, 31(2): 335-357. doi:10.1016/j.hoc.2016.11.003.
[54] Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma[J]. Blood, 2017, 130(25): 2709-2717. doi:10.1182/blood-2017-05-780049.
[55] Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase ib study[J]. J Clin Oncol, 2016, 34(23): 2698-2704. doi:10.1200/jco.2015.65.9789.
[56] Shi Y, Jia B, Xu W, et al. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China[J]. J Hematol Oncol, 2017, 10(1): 69. doi:10.1186/s13045-017-0439-6.
[57] Amengual JE, Lichtenstein R, Lue J, et al. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma[J]. Blood, 2018, 131(4): 397-407. doi:10.1182/blood-2017-09-806737.
[58] Horwitz S, O'Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma(ECHELON-2): a global, double-blind, randomised, phase 3 trial[J]. Lancet, 2019, 393(10168): 229-240. doi:10.1016/s0140-6736(18)32984-2.
[59] Ramos CA, Grover NS, Beaven AW, et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma[J]. J Clin Oncol, 2020, 38(32): 3794-3804. doi:10.1200/JCO.20.01342.
[1] 温立婷,李旭,高伟,胡田勇,曾宪海,查定军. 17例中耳术后迟发性面瘫的临床特征分析[J]. 山东大学耳鼻喉眼学报, 2022, 36(5): 1-5.
[2] 宋晴 宋西成. 安罗替尼联合治疗在肿瘤治疗中的研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(5): 106-112.
[3] 黄扬周,傅丽华,吴巧莲,黄霞,林隽,叶青. 乳突结节性筋膜炎误诊1例[J]. 山东大学耳鼻喉眼学报, 2022, 36(5): 119-121.
[4] 龚霄阳,李旺,陈曦. 原发性咽旁间隙肿瘤67例回顾性分析[J]. 山东大学耳鼻喉眼学报, 2022, 36(4): 60-65.
[5] 张礼俊, 胥然, 罗继芳, 刘国旗, 何千, 李玮, 蒋振华. 头颈肿瘤游离皮瓣修复术后皮瓣坏死及皮瓣相关并发症影响因素分析[J]. 山东大学耳鼻喉眼学报, 2022, 36(4): 86-90.
[6] 毛泽凡陈曦,程雷. 喉神经内分泌癌的研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(4): 114-119.
[7] 王媚 李志海. 喉癌干细胞:克服多药耐药性的潜在治疗靶点[J]. 山东大学耳鼻喉眼学报, 2022, 36(4): 120-128.
[8] 陈家宏,王琳,姜彦,于龙刚,张继生,张志勇,孔静文. 原发性鼻腔鼻窦骨外尤文肉瘤/外周原始神经外胚层肿瘤2例并文献复习[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 290-296.
[9] 姚周周，张革化,常利红. 汉防己甲素调控肿瘤细胞自噬的研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(2): 139-143.
[10] 杨扬, 王晓旭, 张杰. 儿童中耳胆脂瘤诊治进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(1): 1-6.
[11] 高信忠, 林宗通, 沈翎, 刘平凡, 林兴, 许杨杨. 咽鼓管球囊扩张联合腺样体切除术治疗儿童分泌性中耳炎疗效分析[J]. 山东大学耳鼻喉眼学报, 2022, 36(1): 7-12.
[12] 李玲,李聪,孙岩,陈良. 婴儿中耳胚胎型横纹肌肉瘤1例并文献复习[J]. 山东大学耳鼻喉眼学报, 2022, 36(1): 55-59.
[13] 焦雪梅,杨扬,李春凤,张晓琳. 鼓膜置管对分泌性中耳炎患儿咽鼓管功能的影响[J]. 山东大学耳鼻喉眼学报, 2022, 36(1): 60-63.
[14] 陈坤,陆慧,黄琦,李磊,孟国珍,杨军,侯东明. 小儿先天性鼻腔鼻窦肿物的临床诊疗观察[J]. 山东大学耳鼻喉眼学报, 2022, 36(1): 81-85.
[15] 万怡宁,张德军,傅则名,郭芳,郭颖媛,管国芳. 磁共振弥散加权成像在先天性中耳胆脂瘤精准诊断与JOS分期中的应用探讨12例[J]. 山东大学耳鼻喉眼学报, 2021, 35(6): 65-69.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 和守盰,陈 斌,殷善开,苏开明,姜 晓 . OSAHS患者UPPP手术前后上气道形态学变化[J]. 山东大学耳鼻喉眼学报, 2008, 22(5): 385 -388 .
[2] 宋西成,张庆泉,夏永宏,刘鲁沂,于鲁欣,王 郜,姜秀良 . 阻塞性睡眠呼吸暂停低通气综合征患者的术后ICU监护[J]. 山东大学耳鼻喉眼学报, 2008, 22(5): 389 -392 .
[3] 薛卫国,孙洁,金铮,石文斌,辛露,林国经,李加耘 . 盐酸左氧氟沙星滴耳液治疗中耳炎的疗效观察[J]. 山东大学耳鼻喉眼学报, 2006, 20(4): 300 -303 .
[4] 张庆泉,李新民,王 强,王有福 . 鼻内镜下犬齿窝径路治疗上颌窦病变[J]. 山东大学耳鼻喉眼学报, 2007, 21(1): 38 -39 .
[5] 董 频,李晓艳,屠理强,孟晴虹,王 桑,谢 晋,姜 彦 . 晚期下咽癌、喉复发癌术后颈部缺损整复组织的选择[J]. 山东大学耳鼻喉眼学报, 2007, 21(5): 385 -387 .
[6] 姜绍红,朱宇宏,王 强,宋西成 . 难治性原发性鼻出血101例[J]. 山东大学耳鼻喉眼学报, 2007, 21(6): 542 -544 .
[7] 王昭迪,时光刚 . 虚拟现实技术在鼻外科的应用[J]. 山东大学耳鼻喉眼学报, 2008, 22(1): 74 -77 .
[8] 雷迅1 ，刘强和1 ，孔中雨1 ，向秋2 ，耿宛平1 ，黄辉3 ，董译元1 ，刘芳贤1
. EGCG对鼻咽癌细胞株裸鼠移植瘤的放疗增敏作用以及对Survivin表达的影响[J]. 山东大学耳鼻喉眼学报, 2009, 23(1): 6 -9 .
[9] 吴世普
. 鼻内镜下联合下鼻道开窗治疗上颌窦真菌球15例[J]. 山东大学耳鼻喉眼学报, 2009, 23(2): 73 -74 .
[10] 刘伟，殷团芳，任基浩. 中耳胆脂瘤的发生及其与细胞凋亡的关系[J]. 山东大学耳鼻喉眼学报, 2010, 24(01): 29 -33 .
网站版权所有 © 2018 《山东大学耳鼻喉眼学报》编辑部　
地址：山东省济南市山大南路27号（250100）电话：+86-0531-88366912 E-mail: ebhxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发